Trial Search Results
Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)
The investigators collected blood and lymphoid tissues routinely discarded during surgery from adults after a routine seasonal influenza vaccination to determine how immune memory develops at the actual site of infection, and how immunization may alter this process.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)
- Biological: Fluzone®
- Biological: FluMist®
1. Generally healthy 18-49 year old male and female patients undergoing tonsillectomy for
obstructive sleep apnea.
2. Willing to complete the informed consent process
3. Availability for follow-up for the planned duration of the study
4. Acceptable medical history by review of inclusion/exclusion criteria
1. Prior off-study vaccination with seasonal influenza vaccine within three months of
2. Life-threatening reactions to previous influenza vaccinations
3. Asthma (contraindication for receipt of LAIV4) for study volunteers; not a
contraindication for enrolling as a pilot phase volunteer receiving IIV4.
4. Allergy to egg or egg products or to vaccine components (including gentamicin,
gelatin, arginine or MSG for participants receiving LAIV4).
5. Active systemic or serious concurrent illness, including febrile illness on the day of
6. History of immunodeficiency (including HIV infection)
7. Known or suspected impairment of immunologic function; may include significant liver
disease, diabetes mellitus treated with insulin or moderate to severe renal disease
8. Hospitalization in the past year for congestive heart failure or emphysema.
9. Chronic Hepatitis B or C.
10. Recent or current use of immunosuppressive medication, including systemic
glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible).
Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable after review
by the investigator.
11. Participants who care for severely immunosuppressed persons that require a protective
environment should not receive LAIV, or should avoid contact with such persons for 7
days after receipt, given the theoretical risk for transmission of the live attenuated
vaccine virus to close contacts. [If yes, may be ineligible]
12. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors
such as breast cancer or prostate cancer with recurrence in the past year, and any
hematologic cancer such as leukemia).
13. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive
medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion
of the investigator might jeopardize volunteer safety or compliance with the protocol.
14. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
medical follow up or hospitalization during the preceding year
15. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet
agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox will be
reviewed by investigators to determine if study participation would affect the
volunteer's safety or compliance with the protocol.
16. Has taken an influenza antiviral medication within 48 hours prior to study vaccination
[For volunteers receiving LAIV; If yes, may not eligible if unable to schedule at an
17. Receipt of blood or blood products within the past 6 months or planned use during the
18. Medical or psychiatric condition or occupational responsibilities that preclude
participant compliance with the protocol
19. Receipt of an inactivated vaccine 14 days prior to study enrollment, or planned
vaccinations prior to completion of last study visit (~ 14 days after study
20. Receipt of a live, attenuated vaccine within 60 days prior to enrollment of planned
vaccination prior to completion of last study visit (~ 14 days after study enrollment)
21. Need for allergy immunization (that cannot be postponed) until after the last study
22. History of Guillain-Barré syndrome
23. Pregnant woman;
24. Breastfeeding woman [if volunteer will receive LAIV4]
25. Use of investigational agents within 30 days prior to enrollment or planned use during
26. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or
donation of platelets within 2 weeks of enrollment or planned donation prior to
completion of the last visit.
27. Any condition which, in the opinion of the investigator, might interfere with
volunteer safety, study objectives or the ability of the participant to understand or
comply with the study protocol.
Ages Eligible for Study
18 Years - 49 Years
Genders Eligible for Study